Nurix Therapeutics Files Proxy Materials
Ticker: NRIX · Form: DEFA14A · Filed: Mar 27, 2026 · CIK: 0001549595
Sentiment: neutral
Topics: proxy-filing, shareholder-materials, corporate-governance
TL;DR
Nurix Therapeutics filed proxy docs on 3/27/26. Shareholders vote soon.
AI Summary
Nurix Therapeutics, Inc. filed a DEFA14A form on March 27, 2026, related to additional definitive proxy soliciting materials. The filing includes various documents, such as the main DEFA14A filing and graphic files, totaling over 400KB in size. The company's mailing and business address is 1600 Sierra Point Parkway, Brisbane, CA 94005.
Why It Matters
This filing indicates that Nurix Therapeutics is engaging in proxy solicitations, which are crucial for shareholder voting on important corporate matters.
Risk Assessment
Risk Level: low — This filing is a routine proxy statement and does not contain information that inherently poses a high risk to investors.
Key Numbers
- 16915 — DEFA14A Document Size (Size of the primary DEFA14A filing in KB.)
- 403947 — GRAPHIC Document Size (Size of the first graphic file in bytes.)
Key Players & Entities
- Nurix Therapeutics, Inc. (company) — Filer of the DEFA14A
- 0001549595 (company) — CIK number for Nurix Therapeutics, Inc.
- 2026-03-27 (date) — Filing date of the DEFA14A
FAQ
What is the purpose of a DEFA14A filing?
A DEFA14A filing is used for additional definitive proxy soliciting materials and Rule 14(a)(12) material, typically related to shareholder meetings and voting.
When was this DEFA14A filing accepted by the SEC?
The filing was accepted on 2026-03-27 at 06:04:00.
What is Nurix Therapeutics, Inc.'s CIK number?
Nurix Therapeutics, Inc.'s CIK number is 0001549595.
Where is Nurix Therapeutics, Inc. located?
The company's mailing and business address is 1600 Sierra Point Parkway, Brisbane, CA 94005.
What SIC code is associated with Nurix Therapeutics, Inc.?
The SIC code is 2834, which corresponds to Pharmaceutical Preparations (CF Office: 03 Life Sciences).
Filing Stats: 129 words · 1 min read · ~1 pages · Grade level 13.2 · Accepted 2026-03-27 06:04:00
Filing Documents
- ny20064945x2_defa14a.htm (DEFA14A) — 17KB
- ny20064945x2_nc01.jpg (GRAPHIC) — 394KB
- ny20064945x2_nc02.jpg (GRAPHIC) — 250KB
- 0001140361-26-011504.txt ( ) — 906KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to 240.14a-12 NURIX THERAPEUTICS, INC. (Name of Registrant as Specified in Its Charter) N/A (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.